Template:Estrogen dosages for menopausal hormone therapy
Jump to navigation
Jump to search
| Route/form | Estrogen | Low | Standard | High | |||
|---|---|---|---|---|---|---|---|
| Oral | Estradiol | 0.5–1 mg/day | 1–2 mg/day | 2–4 mg/day | |||
| Estradiol valerate | 0.5–1 mg/day | 1–2 mg/day | 2–4 mg/day | ||||
| Estradiol acetate | 0.45–0.9 mg/day | 0.9–1.8 mg/day | 1.8–3.6 mg/day | ||||
| Conjugated estrogens | 0.3–0.45 mg/day | 0.625 mg/day | 0.9–1.25 mg/day | ||||
| Esterified estrogens | 0.3–0.45 mg/day | 0.625 mg/day | 0.9–1.25 mg/day | ||||
| Estropipate | 0.75 mg/day | 1.5 mg/day | 3 mg/day | ||||
| Estriol | 1–2 mg/day | 2–4 mg/day | 4–8 mg/day | ||||
| Ethinylestradiola | 2.5 μg/day | 5–15 μg/day | – | ||||
| Nasal spray | Estradiol | 150 μg/day | 300 μg/day | 600 μg/day | |||
| Transdermal patch | Estradiol | 25 μg/dayb | 50 μg/dayb | 100 μg/dayb | |||
| Transdermal gel | Estradiol | 0.5 mg/day | 1–1.5 mg/day | 2–3 mg/day | |||
| Vaginal | Estradiol | 25 μg/day | – | – | |||
| Estriol | 30 μg/day | 0.5 mg 2x/week | 0.5 mg/day | ||||
| IM or SC injection | Estradiol valerate | – | – | 4 mg 1x/4 weeks | |||
| Estradiol cypionate | 1 mg 1x/3–4 weeks | 3 mg 1x/3–4 weeks | 5 mg 1x/3–4 weeks | ||||
| Estradiol benzoate | 0.5 mg 1x/week | 1 mg 1x/week | 1.5 mg 1x/week | ||||
| SC implant | Estradiol | 25 mg 1x/6 months | 50 mg 1x/6 months | 100 mg 1x/6 months | |||
| Footnotes: a = No longer used or recommended, due to health concerns. b = As a single patch applied once or twice per week (worn for 3–4 days or 7 days), depending on the formulation. Note: Dosages are not necessarily equivalent. Sources: [1][2][3][4][5][6][7][8][9][10][11][12][13][14] | |||||||
Template documentationSee also
- Template:Estrogen dosages for breast and prostate cancer
- Template:Medications and dosages used in hormone therapy for transgender women
References
- ↑ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947.
- ↑ Kuhl, Herbert; Wiegratz, Inka (1 January 2008). Klimakterium, Postmenopause und Hormonsubstitution [Climacteric, Postmenopause and Hormone Replacement] (in Deutsch) (4 ed.). UNI-MED-Verlag. p. 188. ISBN 978-3-83742-043-2.
- ↑ Wiegratz, I.; Kuhl, H. (2007). "Praxis der Hormontherapie in der Peri- und Postmenopause" [Practice of hormone therapy in the peri- and postmenopause]. Gynäkologische Endokrinologie. 5 (3): 141–149. doi:10.1007/s10304-007-0194-9. ISSN 1610-2894.
- ↑ Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW (April 2008). "Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause". Climacteric. 11 (2): 108–23. doi:10.1080/13697130801983921. PMID 18365854.
- ↑ Laura Marie Borgelt (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 257–. ISBN 978-1-58528-194-7.
- ↑ DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (23 January 2017). Pharmacotherapy: A Pathophysiologic Approach, Tenth Edition. McGraw-Hill Education. p. 1295. ISBN 978-1-259-58749-8.
- ↑ Warren MP (February 2007). "Historical perspectives in postmenopausal hormone therapy: defining the right dose and duration". Mayo Clin. Proc. 82 (2): 219–26. doi:10.4065/82.2.219. PMID 17290731.
- ↑ Simon JA, Snabes MC (December 2007). "Menopausal hormone therapy for vasomotor symptoms: balancing the risks and benefits with ultra-low doses of estrogen". Expert Opin Investig Drugs. 16 (12): 2005–20. doi:10.1517/13543784.16.12.2005. PMID 18042008.
- ↑ Marc A. Fritz; Leon Speroff (28 March 2012). Clinical Gynecologic Endocrinology and Infertility. Lippincott Williams & Wilkins. pp. 751–753. ISBN 978-1-4511-4847-3.
- ↑ Thomas, John A.; Keenan, Edward J. (6 December 1986). "Estrogens and Antiestrogenic Drugs". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 135–165. doi:10.1007/978-1-4684-5036-1_7. ISBN 978-1-4684-5036-1.
- ↑ Ruggiero, R (2002). "Estrogen: physiology, pharmacology, and formulations for replacement therapy". Journal of Midwifery & Women's Health. 47 (3): 130–138. doi:10.1016/S1526-9523(02)00233-7. ISSN 1526-9523.
- ↑ [1]
- ↑ Laurence Brunton; John Lazo; Keith Parker (13 September 2005). Goodman & Gilman's The Pharmacological Basis of Therapeutics, Eleventh Edition. McGraw Hill Professional. p. 1553. ISBN 978-0-07-160891-6.
These preparations differ widely in their oral potencies; e.g., a dose of 0.625 mg of conjugated estrogens generally is considered equivalent to 5 to 10 μg of ethinyl estradiol.
- ↑ Kutlesic, Ranko; Popovic, Jasmina; Stefanovic, Milan; Vukomanovic, Predrag; Andric, Aleksandra; Milosevic, Jelena (2016). "Menopausal hormone therapy: Benefits and different forms". Medicinski pregled. 69 (7–8): 247–254. doi:10.2298/MPNS1608247K. ISSN 0025-8105. PMID 29693907.